A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors
Main Article Content
Keywords
c-Myc, Max, intrinsically disordered proteins, 10058-F4, 10074-G5, JKY-2-169
Abstract
The use of small molecules to interfere with protein-protein interactions has tremendous therapeutic appeal and is an area of intense interest. Numerous techniques exist to assess these interactions and their disruption. Many, however, require large amounts of protein, do not allow interactions to be followed in real time, are technically demanding or require large capital expenditures and high levels of expertise. Surface plasmon resonance (SPR) represents a convenient alternative to these techniques with virtually none of their disadvantages. We have devised an SPR-based method that allows the heterodimeric association between the c-Myc (Myc) oncoprotein and its obligate partner Max to be quantified in a manner that agrees well with values obtained by other methods. We also adapted it to examine the ability of previously validated small molecules to interfere with Myc-Max heterodimerization and DNA binding. These inhibitors comprised two distinct classes of molecules that inhibit DNA binding by preventing Myc-Max interaction or distorting pre-formed heterodimers and rendering them incapable of DNA binding. Our studies also point out several potential artifacts and pitfalls to be considered when attempting to employ similar SPR-based methods. This technique should be readily adaptable to the study of other protein-protein interactions and their disruption by small molecules.
Downloads
Metrics
References
2. Chakraborty C, Doss CG, Chen L, Zhu H (2014) Evaluating protein-protein interaction (PPI) networks for diseases pathway, target discovery, and drug-design using 'in silico pharmacology'. Curr Protein Pept Sci 15: 561-571.
3. Lage K (2014) Protein-protein interactions and genetic diseases: The interactome. Biochim Biophys Acta 1842: 1971-1980.
4. Fletcher S, Hamilton AD (2007) Protein-protein interaction inhibitors: small molecules from screening techniques. Curr Top Med Chem 7: 922-927.
5. Koehler AN (2010) A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol 14: 331-340.
6. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
7. Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-1217.
8. Prochownik EV, Vogt PK (2010) Therapeutic Targeting of Myc. Genes Cancer 1: 650-659.
9. Fletcher S, Prochownik EV (2014) Small-molecule inhibitors of the Myc oncoprotein. Biochim Biophys Acta: In Press.
10. Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016.
11. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, et al. (2008) Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
12. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, et al. (2008) c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27: 1905-1915.
13. Tu WB, Helander S, Pilstal R, Hickman KA, Lourenco C, et al. (2014) Myc and its interactors take shape. Biochim Biophys Acta: In Press.
14. Yin X, Giap C, Lazo JS, Prochownik EV (2003) Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22: 6151-6159.
15. Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, et al. (2007) Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 6: 2399-2408.
16. Mustata G, Follis AV, Hammoudeh DI, Metallo SJ, Wang H, et al. (2009) Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem 52: 1247-1250.
17. Yap JL, Wang H, Hu A, Chauhan J, Jung KY, et al. (2013) Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorg Med Chem Lett 23: 370-374.
18. Wang H, Chauhan J, Hu A, Pendleton K, Yap JL, et al. (2013) Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. Oncotarget 4: 936-947.
19. Chauhan J, Wang H, Yap JL, Sabato PE, Hu A, et al. (2014) Discovery of methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization. ChemMedChem 9: 2274-2285.
20. Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ (2008) Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol 15: 1149-1155.
21. Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ (2009) Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc 131: 7390-7401.
22. Jung KY, Wang H, Teriete P, Yap JL, Chen L, et al. (2015) Perturbation of the c-Myc-Max Protein-Protein Interaction via Synthetic alpha-Helix Mimetics. J Med Chem: In Press.
23. Berg T (2011) Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Top Microbiol Immunol 348: 139-149.
24. Muller I, Larsson K, Frenzel A, Oliynyk G, Zirath H, et al. (2014) Targeting of the MYCN protein with small molecule c-MYC inhibitors. PLoS One 9: e97285.
25. Beltran H (2014) The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential. Mol Cancer Res 12: 815-822.
26. Zirath H, Frenzel A, Oliynyk G, Segerstrom L, Westermark UK, et al. (2013) MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A 110: 10258-10263.
27. Ferre-D'Amare AR, Prendergast GC, Ziff EB, Burley SK (1993) Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature 363: 38-45.
28. Nair SK, Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112: 193-205.
29. Fieber W, Schneider ML, Matt T, Krautler B, Konrat R, et al. (2001) Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. J Mol Biol 307: 1395-1410.
30. Prochownik EV, VanAntwerp ME (1993) Differential patterns of DNA binding by myc and max proteins. Proc Natl Acad Sci U S A 90: 960-964.
31. Zhang H, Fan S, Prochownik EV (1997) Distinct roles for MAX protein isoforms in proliferation and apoptosis. J Biol Chem 272: 17416-17424.
32. Follis AV, Hammoudeh DI, Daab AT, Metallo SJ (2009) Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg Med Chem Lett 19: 807-810.
Article Sidebar
Article Details
Authors who publish with JBM agree to the following terms:
- Authors retain copyright and grant JBM right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
